Table 3.
ORs-like | SE | 95% CI | P value | |
Monocyclic pattern | ||||
Base outcome | ||||
Polycyclic pattern | ||||
Cluster 1 | Reference | |||
Cluster 2 | 1.42 | 0.43 | 0.78 to 2.57 | 0.252 |
Cluster 3 | 0.66 | 0.31 | 0.27 to 1.64 | 0.373 |
Cluster 4 | 1.99 | 0.72 | 0.98 to 4.04 | 0.058 |
Chronic pattern | ||||
Cluster 1 | Reference | |||
Cluster 2 | 1.31 | 0.44 | 0.68 to 2.53 | 0.424 |
Cluster 3 | 0.40 | 0.24 | 0.12 to 1.31 | 0.132 |
Cluster 4 | 1.45 | 0.60 | 0.65 to 3.26 | 0.366 |
Mortality | ||||
Cluster 1 | Reference | |||
Cluster 2 | 4.56 | 3.73 | 0.92 to 22.63 | 0.064 |
Cluster 3 | Not estimable | |||
Cluster 4 | 11.03 | 9.10 | 2.19 to 55.60 | 0.004 |
χ2 = 21.68; p=0.010 | ||||
Monocyclic pattern | ||||
Base outcome | ||||
Polycyclic pattern | ||||
Cluster 1 | Reference | |||
Cluster 2 | 1.46 | 0.45 | 0.80 to 2.67 | 0.220 |
Cluster 3 | 0.65 | 0.30 | 0.26 to 1.62 | 0.358 |
Cluster 4 | 2.00 | 0.73 | 0.98 to 4.07 | 0.057 |
Male sex | 0.96 | 0.25 | 0.58 to 1.60 | 0.884 |
MAS | 1.25 | 0.47 | 0.60 to 2.61 | 0.552 |
Chronic pattern | ||||
Cluster 1 | Reference | |||
Cluster 2 | 1.28 | 0.44 | 0.66 to 2.51 | 0.468 |
Cluster 3 | 0.41 | 0.25 | 0.13 to 1.35 | 0.144 |
Cluster 4 | 1.36 | 0.57 | 0.60 to 3.07 | 0.461 |
Male sex | 1.67 | 0.49 | 0.94 to 2.97 | 0.079 |
MAS | 1.21 | 0.52 | 0.52 to 2.82 | 0.652 |
Mortality | ||||
Cluster 1 | Reference | |||
Cluster 2 | 5.99 | 5.07 | 0.94 to 31.48 | 0.064 |
Cluster 3 | Not estimable | |||
Cluster 4 | 9.55 | 8.07 | 1.82 to 49.99 | 0.008 |
Male sex | 2.36 | 1.29 | 0.80 to 6.91 | 0.118 |
MAS | 5.99 | 3.52 | 1.89 to 18.95 | 0.002 |
χ2 = 37.48; p=0.001 |
Bold values are statistically significant results.
MAS, macrophage activation syndrome.